Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-02-28

Clinical Trial Update: Sapropterin as a Treatment for Autistic Disorder [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating sapropterin as a treatment for autism spectrum disorder has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • KUVAN (Sapropterin dihydrochloride)

Snippet

Sponsor: The Children's Health Council | Conditions: Autistic Disorder | Phase 2 | Status: COMPLETED | Results posted: 2014-02-28